These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 22426408)

  • 1. Weekly paclitaxel-carboplatin regimen in patients with primary advanced or recurrent endometrial carcinoma.
    Vandenput I; Vergote I; Neven P; Amant F
    Int J Gynecol Cancer; 2012 May; 22(4):617-22. PubMed ID: 22426408
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Efficacy of Low-Dose Paclitaxel Added to Combination Chemotherapy of Carboplatin and Gemcitabine or Pegylated Liposomal Doxorubicin.
    Nagao S; Iwasa N; Kurosaki A; Nishikawa T; Hanaoka T; Hasegawa K; Fujiwara K
    Int J Gynecol Cancer; 2016 Mar; 26(3):443-8. PubMed ID: 26807640
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Leuven dose-dense paclitaxel/carboplatin regimen in patients with primary advanced or recurrent endometrial carcinoma.
    Vandenput I; Vergote I; Leunen K; Berteloot P; Neven P; Amant F
    Int J Gynecol Cancer; 2009 Aug; 19(6):1147-51. PubMed ID: 19820384
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of advanced or recurrent endometrial carcinoma with doxorubicin in patients progressing after paclitaxel/carboplatin: Memorial Sloan-Kettering Cancer Center experience from 1995 to 2009.
    Makker V; Hensley ML; Zhou Q; Iasonos A; Aghajanian CA
    Int J Gynecol Cancer; 2013 Jun; 23(5):929-34. PubMed ID: 23598889
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined chemotherapy regimen of carboplatin and paclitaxel as adjuvant treatment for papillary serous and clear cell endometrial cancer.
    Shechter-Maor G; Bruchim I; Ben-Harim Z; Altaras M; Fishman A
    Int J Gynecol Cancer; 2009 May; 19(4):662-4. PubMed ID: 19509567
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Carboplatin and nonpegylated liposomal doxorubicin in primary advanced or recurrent endometrial cancer: a phase 2 trial conducted by AGO Austria.
    Volgger B; Zeimet AG; Reinthaller A; Petru E; Schauer C; Klein M; Sevelda-Schwarzgruber U; Bogner G; Wolfram G; Marth C
    Int J Gynecol Cancer; 2015 Feb; 25(2):257-62. PubMed ID: 25611899
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Weekly low-dose paclitaxel and carboplatin in the treatment of advanced or recurrent cervical and endometrial cancer.
    Secord AA; Havrilesky LJ; Carney ME; Soper JT; Clarke-Pearson DL; Rodriguez GC; Berchuck A
    Int J Clin Oncol; 2007 Feb; 12(1):31-6. PubMed ID: 17380438
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of doxorubicin after progression on carboplatin and paclitaxel in advanced or recurrent endometrial cancer: a retrospective analysis of patients treated at the Brazilian National Cancer Institute (INCA).
    Moreira E; Paulino E; Ingles Garces ÁH; Fontes Dias MS; Saramago M; de Moraes Lino da Silva F; Thuler LCS; de Melo AC
    Med Oncol; 2018 Jan; 35(3):20. PubMed ID: 29387971
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bevacizumab combined with platinum-taxane chemotherapy as first-line treatment for advanced ovarian cancer: a prospective observational study of safety and efficacy in Japanese patients (JGOG3022 trial).
    Komiyama S; Kato K; Inokuchi Y; Takano H; Matsumoto T; Hongo A; Asai-Sato M; Arakawa A; Kamiura S; Tabata T; Takeshima N; Sugiyama T
    Int J Clin Oncol; 2019 Jan; 24(1):103-114. PubMed ID: 30030657
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A feasibility study of sequential doublet chemotherapy comprising carboplatin-doxorubicin and carboplatin-paclitaxel for advanced endometrial adenocarcinoma and carcinosarcoma.
    Ang JE; Shah RN; Everard M; Keyzor C; Coombes I; Jenkins A; Thomas K; A'Hern R; Jones RL; Blake P; Gabra H; Hall G; Gore ME; Kaye SB
    Ann Oncol; 2009 Nov; 20(11):1787-93. PubMed ID: 19542250
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of primary advanced and recurrent endometrial carcinoma with a combination of carboplatin and paclitaxel-long-term follow-up.
    Sorbe B; Andersson H; Boman K; Rosenberg P; Kalling M
    Int J Gynecol Cancer; 2008; 18(4):803-8. PubMed ID: 17944917
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Salvage chemotherapy in recurrent platinum-resistant or refractory epithelial ovarian cancer with Carboplatin and distearoylphosphatidylcholine pegylated liposomal Doxorubicin (lipo-dox®).
    Khemapech N; Oranratanaphan S; Termrungruanglert W; Lertkhachonsuk R; Vasurattana A
    Asian Pac J Cancer Prev; 2013; 14(3):2131-5. PubMed ID: 23679331
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase 1 and 2 study of carboplatin and pralatrexate in patients with recurrent, platinum-sensitive ovarian, fallopian tube, or primary peritoneal cancer.
    Del Carmen MG; Supko JG; Horick NK; Rauh-Hain JA; Clark RM; Campos SM; Krasner CN; Atkinson T; Birrer MJ
    Cancer; 2016 Nov; 122(21):3297-3306. PubMed ID: 27421044
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High Efficacy and Low Toxicity of the Modified Docetaxel and Carboplatin Protocol in Patients with Recurrent Ovarian Cancer-A Phase 2 Cohort Study.
    Bruchim I; Weeg N; Alpert Y; Sade D; Piura E; Fishman A
    Int J Gynecol Cancer; 2016 May; 26(4):640-7. PubMed ID: 27101523
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment outcomes of paclitaxel for refractory or recurrent epithelial ovarian cancer patients in Thailand.
    Pitakkarnkul S; Tangjitgamol S; Srijaipracharoen S; Manusirivithaya S; Pataradool K; Prutthiphongsit W; Khunnarong J; Thavaramara T
    Asian Pac J Cancer Prev; 2013; 14(4):2421-7. PubMed ID: 23725151
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adenosine triphosphate-based chemotherapy response assay predicts long-term survival of primary epithelial ovarian cancer.
    Li LY; Kim SW; Nam EJ; Lee J; Kim S; Kim YT
    Int J Gynecol Cancer; 2019 Feb; 29(2):334-340. PubMed ID: 30718314
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increased incidence of severe gastrointestinal events with first-line paclitaxel, carboplatin, and vorinostat chemotherapy for advanced-stage epithelial ovarian, primary peritoneal, and fallopian tube cancer.
    Mendivil AA; Micha JP; Brown JV; Rettenmaier MA; Abaid LN; Lopez KL; Goldstein BH
    Int J Gynecol Cancer; 2013 Mar; 23(3):533-9. PubMed ID: 23385285
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A trial of outpatient paclitaxel and carboplatin for advanced, recurrent, and histologic high-risk endometrial carcinoma: preliminary report.
    Price FV; Edwards RP; Kelley JL; Kunschner AJ; Hart LA
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-78-S15-82. PubMed ID: 9346228
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Paclitaxel and carboplatin, alone or with irradiation, in advanced or recurrent endometrial cancer: a phase II study.
    Hoskins PJ; Swenerton KD; Pike JA; Wong F; Lim P; Acquino-Parsons C; Lee N
    J Clin Oncol; 2001 Oct; 19(20):4048-53. PubMed ID: 11600606
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Weekly paclitaxel/carboplatin in the treatment of locally advanced, recurrent, or metastatic vulvar cancer.
    Han SN; Vergote I; Amant F
    Int J Gynecol Cancer; 2012 Jun; 22(5):865-8. PubMed ID: 22552830
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.